Patents by Inventor C. Frank Bennett

C. Frank Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240200067
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C9ORF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: June 6, 2023
    Publication date: June 20, 2024
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Eric E. Swayze
  • Patent number: 11834660
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: December 5, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Gene Hung, C. Frank Bennett
  • Patent number: 11781135
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: October 10, 2023
    Assignees: Washington University, Biogen MA Inc.
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo
  • Publication number: 20230183696
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject.
    Type: Application
    Filed: November 22, 2022
    Publication date: June 15, 2023
    Applicant: Biogen MA Inc.
    Inventors: Frank Rigo, C. Frank Bennett
  • Publication number: 20230174987
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 21, 2022
    Publication date: June 8, 2023
    Applicants: Ionis Pharmaceuticals, Inc., University of Rochester
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Publication number: 20230159919
    Abstract: The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA. In certain embodiments, such modified oligonucleotides provide improved properties of scrRNA.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 25, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Meghdad Rahdar, Thazha P. Prakash, Eric E. Swayze, C. Frank Bennett
  • Publication number: 20230108340
    Abstract: Provided herein are methods of administering ISIS 443139 for ameliorating Huntington's disease, reducing HTT RNA, reducing mHTT RNA, reducing HTT protein, or reducing mHTT protein in a human subject in need thereof. In certain instances, methods are useful for ameliorating at least one symptom of Huntington's disease. Such symptoms of Huntington's disease include, but are not limited to, brain atrophy, muscle atrophy, nerve degeneration, uncontrolled movement, difficulty swallowing, difficulty speaking, anxiety and depression.
    Type: Application
    Filed: February 19, 2021
    Publication date: April 6, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Daniel A. Norris, Anne V. Smith, Roger Lane
  • Patent number: 11535848
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: December 27, 2022
    Assignee: Biogen MA Inc.
    Inventors: Frank Rigo, C. Frank Bennett
  • Publication number: 20220403386
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).
    Type: Application
    Filed: January 18, 2022
    Publication date: December 22, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • Publication number: 20220372473
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a pyruvate kinase M transcript. Certain such compounds are useful for hybridizing to a pyruvate kinase M transcript, including but not limited to a pyruvate kinase M transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the pyruvate kinase M transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with cancer.
    Type: Application
    Filed: December 16, 2021
    Publication date: November 24, 2022
    Inventors: Frank Rigo, C. Frank Bennett, Adrian R. Krainer, Zhenxun Wang
  • Patent number: 11492617
    Abstract: In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide complementary to a nucleic acid transcript. In certain such embodiments, the modified oligonucleotide does not interact or interacts poorly with a mRNP complex or granule. In certain such embodiments the modifications and/or motifs of the modified oligonucleotide do not promote interaction with a mRNP complex or granule. In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide thereby reducing the size or amount of protein aggregation in the cell. In certain such embodiments, the protein aggregate is a mRNP granule. In certain such embodiments, the modifications and/or motifs of the modified oligonucleotide promote interaction with a protein aggregate, such as a mRNP granule, that results in disruption of the protein aggregate.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: November 8, 2022
    Assignee: Ionis Pharmaceuticals, Inc
    Inventors: C. Frank Bennett, Xue-hai Liang, Wen Shen
  • Patent number: 11421231
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: August 23, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 11414657
    Abstract: The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA. In certain embodiments, such modified oligonucleotides provide improved properties of scrRNA.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 16, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Meghdad Rahdar, Thazha P. Prakash, Eric E. Swayze, C. Frank Bennett
  • Publication number: 20220143066
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a MaTAR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate breast cancer in an individual in need.
    Type: Application
    Filed: June 15, 2021
    Publication date: May 12, 2022
    Inventors: David L. Spector, Sarah Daniela Diermeier, Frank Rigo, C. Frank Bennett, Susan M. Freier, Gayatri Arun, Kung-Chi Chang
  • Patent number: 11236330
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a pyruvate kinase M transcript. Certain such compounds are useful for hybridizing to a pyruvate kinase M transcript, including but not limited to a pyruvate kinase M transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the pyruvate kinase M transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with cancer.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: February 1, 2022
    Assignees: Ionis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: Frank Rigo, C. Frank Bennett, Adrian R. Krainer, Zhenxun Wang
  • Patent number: 11198867
    Abstract: Certain embodiments are directed to methods and compounds for modulating expression of SMN. In certain embodiments at least two compounds are used: a first compound for inhibiting SMN-NAT and increasing expression of SMN, and a second compound for modulating the splicing of SMN. Such methods and compounds are useful for increasing expression exon 7 containing SMN mRNA in cells and animals.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 14, 2021
    Assignees: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
  • Patent number: 11162096
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 2, 2021
    Assignees: Ionis Pharmaceuticals, Inc, The Regents of the University of California, Ludwig Institute for Cancer
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Patent number: 11066668
    Abstract: The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene. Certain such compounds are useful for hybridizing to a portion of the IKBKAP gene, including but not limited to a portion of the IKBKAP gene in a cell. In certain embodiments, such hybridization results in modulation of splicing of the IKBKAP gene. In certain embodiments, the IKBKAP gene includes a mutation that results in defective splicing and a truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in a decrease in the amount of defective splicing and truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in an increase in the amount of normal splicing and functional, full-length IKAP protein. In certain embodiments, oligonucleotides are used to treat Familial Dysautonomia.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: July 20, 2021
    Assignees: Ionis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Frank Rigo, Adrian R. Krainer, Rahul Sinha
  • Patent number: 11058709
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a MaTAR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate breast cancer in an individual in need.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: Ionis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: David L. Spector, Sarah Daniela Diermeier, Frank Rigo, C. Frank Bennett, Susan M. Freier, Gayatri Arun, Kung-Chi Chang
  • Publication number: 20210169916
    Abstract: Provided are methods for reducing the amount or activity of C9ORF72 RNA, and in certain instances of reducing the amount of C9ORF72 protein, in an animal. Such methods are useful to prevent or ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include anxiety, reduced spatial learning, and memory loss. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: July 23, 2020
    Publication date: June 10, 2021
    Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Jie Jiang, Qiang Zhu, Clotilde Lagier-Tourene